This company has been marked as potentially delisted and may not be actively trading.

Hudson Executive Investment (HEC) Competitors

HEC vs. BTTX, UPHL, OPK, ABUS, and DSGN

Should you be buying Hudson Executive Investment stock or one of its competitors? The main competitors of Hudson Executive Investment include Better Therapeutics (BTTX), UpHealth (UPHL), OPKO Health (OPK), Arbutus Biopharma (ABUS), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector.

How does Hudson Executive Investment compare to Better Therapeutics?

Hudson Executive Investment (NASDAQ:HEC) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

: 73.4% of Hudson Executive Investment shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, Hudson Executive Investment's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.
Company Overall Sentiment
Hudson Executive Investment Neutral
Better Therapeutics Neutral
: Better Therapeutics' return on equity of 0.00% beat Hudson Executive Investment's return on equity.
Company Net Margins Return on Equity Return on Assets
Hudson Executive Investment N/A -337.48% -4.06%
Better Therapeutics N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hudson Executive Investment N/A N/A -$27.24M N/A N/A
Better Therapeutics N/A N/A -$39.76M -$0.78 N/A

Company	Overall Sentiment
Hudson Executive Investment	Neutral
Better Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Hudson Executive Investment	N/A	-337.48%	-4.06%
Better Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hudson Executive Investment	N/A	N/A	-$27.24M	N/A	N/A
Better Therapeutics	N/A	N/A	-$39.76M	-$0.78	N/A

Summary

Better Therapeutics beats Hudson Executive Investment on 3 of the 5 factors compared between the two stocks.

How does Hudson Executive Investment compare to UpHealth?

Hudson Executive Investment (NASDAQ:HEC) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

: In the previous week, Hudson Executive Investment's average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.
Company Overall Sentiment
Hudson Executive Investment Neutral
UpHealth Neutral
: Hudson Executive Investment has higher earnings, but lower revenue than UpHealth.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hudson Executive Investment N/A N/A -$27.24M N/A N/A
UpHealth $130M 0.00 -$56.42M $1.47 N/A
: UpHealth's return on equity of 0.00% beat Hudson Executive Investment's return on equity.
Company Net Margins Return on Equity Return on Assets
Hudson Executive Investment N/A -337.48% -4.06%
UpHealth N/A N/A N/A
: 73.4% of Hudson Executive Investment shares are held by institutional investors. Comparatively, 56.1% of UpHealth shares are held by institutional investors. 34.2% of UpHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Overall Sentiment
Hudson Executive Investment	Neutral
UpHealth	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hudson Executive Investment	N/A	N/A	-$27.24M	N/A	N/A
UpHealth	$130M	0.00	-$56.42M	$1.47	N/A

Company	Net Margins	Return on Equity	Return on Assets
Hudson Executive Investment	N/A	-337.48%	-4.06%
UpHealth	N/A	N/A	N/A

Summary

UpHealth beats Hudson Executive Investment on 4 of the 6 factors compared between the two stocks.

How does Hudson Executive Investment compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Hudson Executive Investment (NASDAQ:HEC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

: Hudson Executive Investment has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Hudson Executive Investment's return on equity.
Company Net Margins Return on Equity Return on Assets
OPKO Health -36.63% -16.78% -10.98%
Hudson Executive Investment N/A -337.48% -4.06%
: 64.6% of OPKO Health shares are held by institutional investors. Comparatively, 73.4% of Hudson Executive Investment shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: OPKO Health currently has a consensus target price of $1.55, suggesting a potential upside of 37.17%. Given OPKO Health's stronger consensus rating and higher probable upside, equities analysts clearly believe OPKO Health is more favorable than Hudson Executive Investment.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OPKO Health
1 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.17
Hudson Executive Investment
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, OPKO Health had 20 more articles in the media than Hudson Executive Investment. MarketBeat recorded 20 mentions for OPKO Health and 0 mentions for Hudson Executive Investment. OPKO Health's average media sentiment score of 0.53 beat Hudson Executive Investment's score of 0.00 indicating that OPKO Health is being referred to more favorably in the media.
Company Overall Sentiment
OPKO Health Positive
Hudson Executive Investment Neutral
: Hudson Executive Investment has lower revenue, but higher earnings than OPKO Health.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OPKO Health $606.90M 1.41 -$225.68M -$0.27 N/A
Hudson Executive Investment N/A N/A -$27.24M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Hudson Executive Investment	N/A	-337.48%	-4.06%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Hudson Executive Investment	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
OPKO Health	Positive
Hudson Executive Investment	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.41	-$225.68M	-$0.27	N/A
Hudson Executive Investment	N/A	N/A	-$27.24M	N/A	N/A

Summary

OPKO Health beats Hudson Executive Investment on 8 of the 12 factors compared between the two stocks.

How does Hudson Executive Investment compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Hudson Executive Investment (NASDAQ:HEC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

: Arbutus Biopharma presently has a consensus target price of $5.00, suggesting a potential upside of 13.77%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Arbutus Biopharma is more favorable than Hudson Executive Investment.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arbutus Biopharma
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Hudson Executive Investment
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Hudson Executive Investment has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Hudson Executive Investment's return on equity.
Company Net Margins Return on Equity Return on Assets
Arbutus Biopharma -237.88% -42.39% -32.48%
Hudson Executive Investment N/A -337.48% -4.06%
: 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 73.4% of Hudson Executive Investment shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, Arbutus Biopharma had 1 more articles in the media than Hudson Executive Investment. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for Hudson Executive Investment. Arbutus Biopharma's average media sentiment score of 1.27 beat Hudson Executive Investment's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Company Overall Sentiment
Arbutus Biopharma Positive
Hudson Executive Investment Neutral
: Hudson Executive Investment has lower revenue, but higher earnings than Arbutus Biopharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arbutus Biopharma $14.08M 61.47 -$33.50M -$0.17 N/A
Hudson Executive Investment N/A N/A -$27.24M N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hudson Executive Investment	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-237.88%	-42.39%	-32.48%
Hudson Executive Investment	N/A	-337.48%	-4.06%

Company	Overall Sentiment
Arbutus Biopharma	Positive
Hudson Executive Investment	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.47	-$33.50M	-$0.17	N/A
Hudson Executive Investment	N/A	N/A	-$27.24M	N/A	N/A

Summary

Arbutus Biopharma beats Hudson Executive Investment on 8 of the 12 factors compared between the two stocks.

How does Hudson Executive Investment compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Hudson Executive Investment (NASDAQ:HEC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Design Therapeutics N/A N/A -$69.79M -$1.20 N/A
Hudson Executive Investment N/A N/A -$27.24M N/A N/A
: Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 23.04%. Given Design Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Design Therapeutics is more favorable than Hudson Executive Investment.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Design Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.86
Hudson Executive Investment
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Design Therapeutics had 11 more articles in the media than Hudson Executive Investment. MarketBeat recorded 11 mentions for Design Therapeutics and 0 mentions for Hudson Executive Investment. Design Therapeutics' average media sentiment score of 0.62 beat Hudson Executive Investment's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Design Therapeutics Positive
Hudson Executive Investment Neutral
: Design Therapeutics' return on equity of -33.07% beat Hudson Executive Investment's return on equity.
Company Net Margins Return on Equity Return on Assets
Design Therapeutics N/A -33.07% -31.29%
Hudson Executive Investment N/A -337.48% -4.06%
: 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of Hudson Executive Investment shares are owned by institutional investors. 23.5% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Hudson Executive Investment	N/A	N/A	-$27.24M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Hudson Executive Investment	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Design Therapeutics	Positive
Hudson Executive Investment	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Hudson Executive Investment	N/A	-337.48%	-4.06%

Summary

Design Therapeutics beats Hudson Executive Investment on 8 of the 11 factors compared between the two stocks.

Get Hudson Executive Investment News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEC vs. The Competition

Export

Metric	Hudson Executive Investment	Health Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$213.62M	$2.52M	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	N/A	N/A	29.25	27.07
Price / Sales	N/A	N/A	504.68	73.47
Price / Cash	N/A	N/A	43.30	53.90
Price / Book	43.00	N/A	9.67	6.69
Net Income	-$27.24M	-$39.76M	$3.55B	$332.64M

Hudson Executive Investment Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEC Hudson Executive Investment	N/A	$5.16 flat	N/A	N/A	$213.62M	N/A	N/A	N/A
BTTX Better Therapeutics	N/A	$0.00 flat	N/A	N/A	$4K	N/A	N/A	40
UPHL UpHealth	N/A	$0.00 flat	N/A	N/A	$2K	$130M	N/A	1,750
OPK OPKO Health	2.8478 of 5 stars	$1.10 -2.2%	$1.55 +40.9%	N/A	$853.95M	$581.12M	N/A	1,373	Earnings Report
ABUS Arbutus Biopharma	0.9076 of 5 stars	$4.32 +2.9%	$5.00 +15.7%	N/A	$850.78M	$14.08M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hudson Executive Investment (HEC) Competitors

HEC vs. BTTX, UPHL, OPK, ABUS, and DSGN

How does Hudson Executive Investment compare to Better Therapeutics?

Summary

How does Hudson Executive Investment compare to UpHealth?

Summary

How does Hudson Executive Investment compare to OPKO Health?

Summary

How does Hudson Executive Investment compare to Arbutus Biopharma?

Summary

How does Hudson Executive Investment compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEC vs. The Competition

Hudson Executive Investment Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hudson Executive Investment (HEC) Competitors

HEC vs. BTTX, UPHL, OPK, ABUS, and DSGN

How does Hudson Executive Investment compare to Better Therapeutics?

Summary

How does Hudson Executive Investment compare to UpHealth?

Summary

How does Hudson Executive Investment compare to OPKO Health?

Summary

How does Hudson Executive Investment compare to Arbutus Biopharma?

Summary

How does Hudson Executive Investment compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEC vs. The Competition

Hudson Executive Investment Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools